MultiCell Technologies Inc (MCET)

[Mcetdreamer]

'Euripides90' You just can't make this stuff up!

Thank you. I don't have a problem you reposting anything if you don't charge the message?

I am just saying, MCET's Fa N2-4 immortalized Human Hepatocytes Cell Lines and the KADCYLA are both sold in 2021 by other companies. Both our MCET Patents.

1)
MCET immortalized Human Hepatocytes Patent maintenance fee was paid in full on Dec 18, 2020 by MCET Patent attorney David Lewis. (Please see link below).

Because not-one of many companies Infringing on MCETs immortalized Human Hepatocytes patent patent payed royalties. (Please see below for link.)

Paid in full
Multicell Technology Inc
immortalized Human Hepatocytes patent.

Worldwide applications
2004 CA AT AU JP DE CA EP US EP WO WO JP US 2006 IL.
Application PCT/US2004/033091 events
2003-10-10
Priority to US51050903P
2003-10-10
Priority to US60/510,509
2004-10-07
Application filed by Multicell Technologies, Inc.
2004-10-07
Priority claimed from AU2004322811A
2006-04-20
Publication of WO2006041488A1
2006-09-08
Publication of WO2006041488A8

2)
Instead of me telling you this information.

Google:
immortalized Human Hepatocytes

You should see SCKISUI XenoTech link to their website. Among other companies Infringing on their Patent. (I can't say that enough times)

You should also see who owns this patent from the US Patent Office. I know it comes up on Google. Sometimes, the link will also come up because it is linked to my posts on I-HUB.

3)
This is from SCKISUI own Xenotech website.

Global Distributors
We distribute our world-class DMPK test systems and related products around the globe to ensure researchers and developers everywhere have access to the best tools available to investigate properties of potential life-changing therapies. In addition to North America, we also frequently ship to numerous other regions, such as those listed below. Even if you don’t see your area listed below, please contact us and we’ll likely be able to find a solution. Regardless of your location, simply use the the contact form above and we can connect you with the appropriate representatives.

China
Europe
India
Japan
Singapore
South Korea
And more!

https://www.xenotech.com/in-vitro-test-systems/cell-products/

If you look at the verbiage "our" meaning ownership.

Meaning
SCKISUI XenoTech owns all the rights to the patent for immortalized Human Hepatocytes Cell Lines.

Which is a false and misleading statement. It's just a all-out lie. And for years MCET just sat back and did nothing. When this is there business. They were all smart enough to patent the immortalized Human Hepatocytes patent, but not go after companies Infringing on their patent?

You got to be kidding me?

The proof is in articles and right from the patent office. That the immortalized Human Hepatocytes Patent is owned by Multicell Technology Inc.
(Please see below for link).

You just can't make this stuff up!

But yet, SCKISUI XenoTech is not just selling it, they have enough balls to license it. While Infringing on MCET Patent. (Please see link below).

4)
Now, Barbra Cornett thinks that we are all dumb enough to let this happen?

Snippets from Barbara's email:
The MultiCell -Xeno Tech agreement was terminated. I don’t know what we can do about them continuing to sell our patented cells


Barbra wrote:

Mr. Newmin and I are both now retired, in spite of still being listed in the Yahoo Finance profile.

Mr. Ed Sigmond is now running the company. Perhaps he can update that and answer some questions for you.


Barbra Wrote:
You can email Ed Sigmond at esigmond@aol.

I am copying him on this reply.

(Please see link below for more).

5)
If you Google Ed Sigmond name along with Multicell Technology Inc, you will find. Ed's been vice president, still is a director and probably a few other positions for MCET. So there are many links connecting him to Multicell Technology Inc.

If you didn't know? Barbara Corbett is married to Jerry Newmin. Hence the name Barbra Corbett Newmin. She comes by both names.

Jerry Newmin was and still could be CEO, Chairman and president for many years. He's been with MCET for probably over 20 years. I just think, Jerry, Barbara Newmin and Ed Sigmond got there hand got caught in the cookie jar and now Barbara is blaming at Ed Sigmond. Ok Barbara, is he the mastermind of a scam, embarrassment or fraud.

Please MCET management, come out with the Truth. If you not, I am sure you have grounds to sue me? But you are probably are all involved or just to dumb to protect are patent and s
Do your duties as officers/management, so you can't?

There are Many ways of finding out the truth. The best way would be help from the Justice Department.

6)
Do you have ties to the Justice department? Not to mention any of other departments that might be interested in this Patent Infringement and to investigate MCET management. Please let me know. I will be very happy to go over what I have with them.

If your Google Justice Department and what they do. (Please see next post.)

6.2)
The Justice Department is here to protect investors from corrupt or dishonest management and companies from infringing on their Patents. This includes Multicell Technology Inc, there Management, SCKISUI XenoTech LLC of Kansas, SCKISUI Japanese Collection of Research Bioresources (JCRB) Cell Bank, Tebu-Bio the exclusive European distributor of the JCRB cell lines. And to see what happened to Patent that KADCYLA uses.

6.3)
The Justice Department will protect Multicell Technology Inc Patent for the stockholders.

6.4)
If you haven't noticed, XenoTech is from Japan, this patent also includes/covers companies from Japan Infringing on them.

SCKISUI XenoTech World Headquarters in Kansas, United States. This Patent also cover's the USA.

7)
You should at least hold this stock. When will you have another opportunity to buy Bio Technology stock under a $1.00? That have a Multi- billion Patent. That many companies are Infringing on. Not to mention the MCET patent maintenance fee was just paid in full.



Older post.
A)
History of the problem: patents and Patent infringement companies with Links.

A.1)
Multicell Technologies, Inc. Patent:

immortalized Human Hepatocytes Cell Lines.
WO2006041488A1
WIPO (PCT)

languagesFrenchInventorJin LiuRonald A. Faris
Worldwide applications
2004 WO DE US CA AU US CA WO AT EP EP JP JP 2006 IL
Application PCT/US2004/033091 events
2003-10-10
Priority to US51050903P
2003-10-10
Priority to US60/510,509
2004-10-07

Application filed by Multicell Technologies, Inc.
2004-10-07

Priority claimed from AU2004322811A
2006-04-20
Publication of WO2006041488A1
2006-09-08
Publication of WO2006041488A8

https://patents.google.com/patent/WO2006041488A1/eel


A.2)
Multicell Technology terminated the exclusive license agreement with XenoTech LLC of Kansas for "failure to meet minimum royalty obligations," according to company officials

Click on link:

https://www.bizjournals.com/boston/blog/mass-high-tech/2006/02/multicell-cancels-distribution-deal-with.html


A.3)
2015 XenoTech Expansion 41,500 ft2 facility.
of their Global Headquarters after Impressive Revenue Growth in 2014.

https://www.xenotech.com/about/news/xenotech-plans-expansion-to-new-global-headquarters-after-impressive-revenue-growth-in-2014/



A.3) The Japanese Collection of Research Bioresources, or JCRB, provides one of the most comprehensive cell banks in the world to investigators across the globe for pure and applied science spanning many different fields of research.

National Institute of Biomedical Innovation to bring you access to over 1,600 cell lines as the exclusive provider of JCRB’s comprehensive catalog of cell lines in North America. Our European distributor, tebu-bio, is the exclusive European distributor of the JCRB cell lines

Japanese Collection of Research Bioresources (JCRB) Cell Bank

https://www.xenotech.com/in-vitro-test-systems/cell-products/cell-banks/



A.4) TEBU-BIO ACROSS EUROPE.

tebu-bio across Europe
European distributor, tebu-bio, is the exclusive European distributor of the JCRB cell lines.

Cell Line Offerings:

tebu-bio across Europe
Contact your local tebu-bio office
If you’d like to reach one of our local representatives in many countries throughout Europe, you'll find a
tebu-bio office near to you in the list below.

https://www.tebu-bio.com/cms/1054/Your_local_tebu_bio_contact.html




A.5) They sell Fa N2-4 immortalized Human Hepatocytes Cell Lines on at least 3 Continents, North America, Asia and Europe.

We also know MCET has people working in Mexico, and Brazil. All found on Linkedin with connections linking to each other.

A.6)
XenoTech failure to meet minimum royalty obligations," Why haven't they haven't paid in 14 years along with everyone else?

A.8) PAID IN FULL MCET's Patent Maintenance Fee on 12-18-2020 for their Fa2n-4 and Ea1C-35 ImmortalizedHuman Hepatocytes Cell Lines


IMMORTALIZED HEPATOCYTES

PATENT #

7566567

APPLICATION #

10574163

FILING DATE

03/29/2006

ISSUE DATE

07/28/2009

Payment Window Status

WINDOW

11.5 Year

STATUS

Closed

FEES

Paid

Window

First Day to Pay

Surcharge Starts

Last Day to Pay

Status

Fees

Statement

3.5 Year 07/28/2012 01/29/2013 07/29/2013 Closed Paid Statement

7.5 Year 07/28/2016 01/31/2017 07/28/2017 Closed Paid Statement

11.5 Year 07/28/2020 01/29/2021 07/28/2021 Closed Paid Statement

Patent Holder Information



Customer # 87008

Entity Status UNDISCOUNTED

Phone Number [phone]

Address MultiCell Technologies, Inc.

c/o David Lewis

1250 Aviation Avenue, Suite 200B

San Jose, CA 95110

UNITED STATES


B)
Recently we found out MCET has people working in 3 countries, Brazil, Mexico and the USA.

Why does anyone believe the Newmin’s are retired? Because they said so? Both the Newmin’s are still listed on LinkedIn as Chairman running MCET. They may not be as active? But what corporation has their retired chairman still listed as running the company if there not?


Has Ed Sigmond come forward to say he is in charge? No, does Ed answer emails, No. So Ed isn’t in charge of MCET.


MCET has employees in at least 3 counties that I know of, and they are not working for free.

The Newmin’s are lying because they are being questioned and now getting exposed.


MCET needs to be taken over and audited, the question is how?


MCET has a stock platform that many biotechnology drugs could use.


The Newmin’s are keeping all the profits for years. This needs to stop.


Simona Bot, MD worked for them for years until Oct 2019 researching evaluating new drug candidates in human hepatocellular carcinoma models.


Contact LinkedIn

https://www.linkedin.com/in/simona-bot-md-11724032


If you haven’t been paying attention. This is the same Fa N2-4 immortalized Human Hepatocytes Cell Lines many other companies and universities have been infringing on MCETs Patents for years and Barbara Newmin wrote she didn’t know what they can do about it

I don’t trust the Newmin’s or at this point Ed Sigmond.

Just to let people know, LinkedIn is a secondary resume.
As most people know. LINKEDIN IS NOT A WEBSITE FOR MCET so in saying that, MCET didn’t post anything on LinkedIn. It’s ONLY posted by that individual person as a resume or as a business contact. So this is how and why it’s validated.
MCET has Employees that get paid.
MCET finance are most likely up to date?

MCET has much more going on then a Patent infringement case. And much then I originally thought.

The last 6 posts on MCETs message board.

1) MCET's Employee's are all found separately on LinkedIn resume website currently working on at least 2 continents and 3 countries.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161365885

2) WHO’S REALLY THE BOSS?
MCET's LinkedIn Top Employees &?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161365999


3) THERE SNIPPETS FROM EMAILS I RECEIVED FROM BARBARA!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161366062


4) Multicell technology has at people working in Brazil,

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161366218


5) MCETs: ADCETRIS® (brentuximab vedotin) for injection logo: Sold

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161365835


6) PAID IN FULL MCET’s Patent Maintenance Fee

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161365840



C)


Barbra stated that Ed Sigmond was in charge once I started asking questions about the Fa N2-4 immortalized Human Hepatocytes Cell Lines last summer. I think Ed Sigmond could be a Mastermind and she wants out of it now. Because she is scared now that just getting caught and exposed.


Snippets from Barbara and my emails.

Barbra wrote:

Apparently there is new ownership at our former licensee, XenoTech?

I am unaware of the licensing deal being extended since this.

The MultiCell -Xeno Tech agreement was terminated. I don’t know what we can do about them continuing to sell our patented cells


9.2) Barbra wrote:

You can email Ed Sigmond at esigmond@aol.

I am copying him on this reply.

I don’t follow the message boards or stock activity and am unaware of a holding company deal or any recent stock transactions.

Your ownership percentage information seems very outdated.

Apparently there is new ownership at our former licensee, XenoTech?

I am unaware of the licensing deal being extended since this:

9.3) Barbara wrote:

You can email Ed Sigmond at esigmond@aol.

I am copying him on this reply.

E-mail: [e-mail]

Hi, thank you for your continued interest and your time and attempts to help.

Remember, Mr. Newmin and I no longer work for the company.

We personally do not believe we have any further rights to expired patents.

We have been unable to get a response from Mr. Sigmond. Maybe you can
I


Snippets from Barbara and my emails.

9.2) Barbra wrote:

You can email Ed Sigmond at esigmond@aol.

I am copying him on this reply.

I don’t follow the message boards or stock activity and am unaware of a holding company deal or any recent stock transactions.

Your ownership percentage information seems very outdated.

Apparently there is new ownership at our former licensee, XenoTech?

I am unaware of the licensing deal being extended since this:

9.3) Barbara wrote:

You can email Ed Sigmond at esigmond@aol.

I am copying him on this reply.

E-mail: [e-mail]

Hi, thank you for your continued interest and your time and attempts to help.

Remember, Mr. Newmin and I no longer work for the company.

We personally do not believe we have any further rights to expired patents.

We have been unable to get a response from Mr. Sigmond. Maybe you can

Barbra wrote:

Mr. Newmin and I are both now retired, in spite of still being listed in the Yahoo Finance profile.

Mr. Ed Sigmond is now running the company. Perhaps he can update that and answer some questions for you.



On Mon, Sep 21, 2020, 4:33 PM Barbara Corbett <[e-mail]> wrote:
Hi, again,

I am re-reviewing our correspondence and wondering if you heard back from Mr. Sigmond.
I got no email from him.

Belated condolences for your mother's passing.

I see no record of having gotten a twitter message from anyone re MultiCell. I use Twitter only to promote my art/photography.

The MultiCell -Xeno Tech agreement was terminated. I don't know what we can do about them continuing to sell our patented cells.

"MultiCell Takes Control of Cell Marketing Program

Monday February 6, 6:30 am ET PROVIDENCE, R.I.--(BUSINESS WIRE)--Feb. 6, 2006--MultiCell Technologies, Inc. (OTCBB:MCET - News), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, and a leading supplier of non-tumorigenic immortalized human hepatocytes, announced today it had terminated the exclusive license agreement with XenoTech, LLC of Lenexa, Kansas, effective January 31, 2006, for failure to meet minimum royalty obligations.

Under terms of the 2003 agreement, XenoTech was allowed to sell sub-licenses for the propagation of Multicell's immortalized human liver cells ("hepatocytes"). These cells may be used to develop highly predictive, high-throughput drug development assays for drug discovery, lead optimization and pharmacogenomic studies. Industry statistics show, on the average, it now costs almost $1 billion to develop a new drug. Many drugs fail in development because the human liver cannot process toxic aspects of many new drug candidates. MultiCell believes that highly predictive assays such as ones using its hepatocytes could predict potential failures earlier in the development process thus saving pharmaceutical companies millions of dollars in drug development costs. "We believe our immortalized human hepatocytes are ideal products, which help to fill a currently unmet need within the pharmaceutical industry, and that there are no other consistent products available to pharmaceutical companies for predicting the liver toxicity of new drug compounds," Stephen Chang, Ph.D., President of Multicell explained. "We believe that one of MultiCell's greatest strategic advantages is our management team's ability to move quickly to complete transactions as evidenced in the past six months. We plan to take advantage of this strength by taking direct control of the marketing and selling activities for this key product."

About MultiCell Technologies, Inc.MultiCell Technologies, Inc. is a developer of therapeutic products, and a supplier of immortalized human cell lines for drug discovery applications. With its majority-owned subsidiary MultiCell Immunotherapeutics, Inc., MultiCell is working to commercialize new therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases. MultiCell's cellular systems research labs are in Lincoln, RI. MultiCell Immunotherapeutics is located in San Diego, CA.
For more information about MultiCell see multicelltech.com. Information on our website is not part of this press release.
Caution Regarding Forward-Looking StatementsAny statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". Examples of such forward looking statements include statements regarding contemplated guidance in the investment and financial markets, evaluation of the company's lead drug candidates, or commencement of clinical trials. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2004, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events."


That's all for now.
Best regards
Barbara Corbett
Show quoted text